AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Elongation factor-like GTPase 1 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Elongation factor-like GTPase 1 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Elongation factor-like GTPase 1, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Elongation factor-like GTPase 1. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Elongation factor-like GTPase 1. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Elongation factor-like GTPase 1 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Elongation factor-like GTPase 1
partner:
Reaxense
upacc:
Q7Z2Z2
UPID:
EFL1_HUMAN
Alternative names:
Elongation factor Tu GTP-binding domain-containing protein 1; Elongation factor-like 1; Protein FAM42A
Alternative UPACC:
Q7Z2Z2; A6NKY5; B7Z6I0; Q9H8Z6
Background:
Elongation factor-like GTPase 1, also known as Elongation factor Tu GTP-binding domain-containing protein 1, Elongation factor-like 1, and Protein FAM42A, plays a crucial role in protein synthesis. It is involved in the biogenesis of the 60S ribosomal subunit and translational activation of ribosomes, facilitating the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm. This process is essential for activating ribosomes for translation competence, allowing 80S ribosome assembly, and facilitating EIF6 recycling to the nucleus for 60S rRNA processing and nuclear export.
Therapeutic significance:
Elongation factor-like GTPase 1's involvement in Shwachman-Diamond syndrome 2, characterized by hematopoietic abnormalities, exocrine pancreatic dysfunction, and skeletal dysplasia, highlights its potential as a therapeutic target. Understanding the role of Elongation factor-like GTPase 1 could open doors to potential therapeutic strategies for treating this autosomal recessive disorder.
